Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a hold rating to a buy rating in a report released on Thursday. The brokerage currently has $62.00 price objective on the stock.

According to Zacks, “Fresenius has had a favorable run on the bourse over the last year. A solid full-year guidance instills our confidence on the stock. We believe this is in tune with the ‘Growth Strategy 2020’, under which it aims to boost revenues to $28 billion by 2020, corresponding to an average annual growth rate of around 10%. A wide range of dialysis products, initiatives to gain market traction, strengthened international foothold, strategic acquisitions and divestments act as major catalysts. On the flipside, lackluster performance by the renal pharmaceutical segment is likely to dent Latin-American revenues in the coming quarters. Having a strong international foothold, Fresenius faces the brunt of stringent regulations in almost every country in which it operates. Thus, it has to fulfill specific legal requirements that include tough antitrust laws. Regulatory hurdles and competition in the niche markets are major headwinds.”

Several other equities analysts have also recently weighed in on FMS. Nord/LB reissued a buy rating on shares of Fresenius Medical Care AG & Co. in a report on Wednesday, December 27th. SunTrust Banks set a $62.00 price target on Fresenius Medical Care AG & Co. and gave the company a buy rating in a report on Thursday, December 21st. UBS Group raised Fresenius Medical Care AG & Co. from a sell rating to a neutral rating in a report on Thursday, January 4th. DZ Bank reissued a buy rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, November 13th. Finally, Morgan Stanley cut Fresenius Medical Care AG & Co. from an overweight rating to an equal weight rating in a report on Monday, December 11th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $56.00.

Fresenius Medical Care AG & Co. (NYSE FMS) traded up $0.76 during mid-day trading on Thursday, reaching $55.75. The company had a trading volume of 127,759 shares, compared to its average volume of 113,573. The company has a market cap of $34,169.40, a PE ratio of 25.00, a PEG ratio of 2.30 and a beta of 0.45. Fresenius Medical Care AG & Co. has a fifty-two week low of $40.02 and a fifty-two week high of $55.76. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its quarterly earnings data on Thursday, November 2nd. The company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.02). Fresenius Medical Care AG & Co. had a net margin of 7.04% and a return on equity of 11.51%. analysts predict that Fresenius Medical Care AG & Co. will post 2.38 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. UBS Asset Management Americas Inc. lifted its holdings in shares of Fresenius Medical Care AG & Co. by 3.6% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock valued at $114,000 after buying an additional 81 shares during the period. YorkBridge Wealth Partners LLC increased its stake in shares of Fresenius Medical Care AG & Co. by 19.4% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after purchasing an additional 749 shares in the last quarter. Stifel Financial Corp purchased a new stake in shares of Fresenius Medical Care AG & Co. in the 2nd quarter worth $225,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Fresenius Medical Care AG & Co. in the 3rd quarter worth $239,000. Finally, Pacer Advisors Inc. increased its stake in shares of Fresenius Medical Care AG & Co. by 37.6% in the 3rd quarter. Pacer Advisors Inc. now owns 5,105 shares of the company’s stock worth $250,000 after purchasing an additional 1,394 shares in the last quarter. 3.03% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Fresenius Medical Care AG & Co. (FMS) Upgraded at Zacks Investment Research” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/01/21/fresenius-medical-care-ag-co-fms-upgraded-at-zacks-investment-research.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.